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Recently, with coming of the “omics” era and rapid devel-
opment of basic research in biology and medicine, huge 
information about biology and life has been achieved. 
However, many research results cannot be translated into 
clinical practice. Under this circumstance, the concept of 
“translational research” is raised [1-4] and widely spread. 
“Translational research” is patient-oriented research which 
connects basic medicine and clinical medicine [2]. It means 
more directly and quickly raising questions from clinical 
practice to basic research and translating findings in basic 
research into clinical practice. The process of translational 
research can be summarized as follows: first, according to 
clinical practice, raising clinical problems and refining sci-
entific questions; then, systematic and in-depth research, 
which integrates diverse disciplines, including epidemic 
study, basic research and drug discovery, is carried out; last, 
through research, the potentially effective strategies or 
methods for diagnosing, treating or preventing diseases are 
achieved and translated into clinical practice. Translational 
research has been developed rapidly in recent years. It is 
used to direct research in cardiovascular diseases (CVD), 
cancer, infectious diseases, metabolic diseases, etc.  
Though the concept “translational research” is relatively 
new, the bedside-to-bench-to-bedside translational strategy 
is not original. In the past century, especially in the past 
several decades, many successful studies were done. These 
studies contributed to human health greatly and are good 
examples for translational research. In this review, we will 
choose to talk several of these studies. We hope that these 
successful examples in the past will facilitate us to deeply 
understand translational research in the future. We will talk 
about research in CVD which achieved great progress in the 
past. 
In the mid-20th century, CVD was severe and almost 
accounted for half of all death in the USA [5]. Framingham 
Heart Study, an epidemiologic study, was carried out to 
study CVD in the town of Framingham, Massachusetts in 
1948, with 5209 adult healthy subjects enrolled [6]. The 
detailed information for each subject, including diet, exer-
cise, social relationship, physical examination and medical 
history, was recorded [6]. The study was implemented for 
about 20 years at its first stage. After that, the second gen-
eration and the third generation of subjects were enrolled in 
1971 and in 2002 respectively [7,8]. Up to now, the study 
has lasted more than 60 years. The results from Framing-
ham Heart Study showed that several factors, including high 
LDL cholesterol level, cigarette smoking, hypertension, 
obesity, diabetes, menopause, increased the risk of heart 
diseases, whereas exercise and high HDL cholesterol de-
creased the risk of heart diseases. It also showed that the 
social and physiological factors influenced CVD [9-12]. In 
recent years, with the development of technology in genet-
ics, such as GWAS technology, some genetic factors con-
tributing to CVD, such as chromosome region 9p21 [13,14], 
were found. Therefore, overall, from Framingham Heart 
Study, the causes for CVD, including many environmental 
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and genetic factors, were found. Framingham Heart Study 
changed people’s ideas about CVD, showing that the dis-
ease is preventable. It introduced the term “risk factor” [15], 
which is used widely nowadays. Framingham Heart Study 
is famous for its long duration and outlook and is thought of 
a very successful research program.  
Another research about how statin was developed pro-
vides a good example for drug discovery for treating CVD. 
More than 100 years ago, it was found that there was cho-
lesterol accumulation in the artery walls of people that died 
from myocardial infarction [16]. The later Framingham 
heart study also showed that there was positive correlation 
between total blood cholesterol level and CVD [17]. Bio-
chemical analysis revealed that cholesterol was derived 
from diet or synthesized by human body, so inhibition of 
cholesterol synthesis was a target to lower cholesterol level 
without modifying diet. In early studies, Triparanol, which 
inhibits an enzyme involved in the later stage of cholesterol 
synthesis, was discovered and introduced into clinical trial 
[18]. However, because inhibition of the enzyme led to ac-
cumulation of its substrate desmosterol and caused severe 
side effect, Triparanol was withdrawn [19]. HMG-CoA re-
ductase (HMGR), the rate-limiting enzyme for in vivo syn-
thesis of cholesterol, was another potential target. Since 
inhibition of HMGR did not cause accumulation of its sub-
strate hydroxymethylglutarate which is water soluble and 
could be metabolized through another pathway, HMGR was 
attractive as a target [16]. In the 1970s, one group found the 
first product inhibiting HMGR in a fermentation broth of 
Penicillium citrinum, with the idea that some microorgan-
isms would produce compounds to fight against other or-
ganisms that utilize sterols or other isoprenoids for growth 
[20]. Later, another product in a fermentation broth of As-
pergillus terreus was found [21], which is currently known 
as lovastatin and is widely used. Nowadays, there are di-
verse effective statin drugs for treating CVD [16]. Statin 
was reported to reduce the risk of heart attacks and strokes 
by about one quarter to one third [22–24] and was among 
the most prescribed drug in the world today.  
In addition to epidemic study and drug discovery, some 
other techniques were also developed to treat CVD. As we 
know, CVD is often caused by occlusion of coronary artery. 
Atherosclerosis is the major reason for occlusion. The se-
vere atherosclerotic plaques, especially those unstable ath-
erosclerotic plaques, are susceptible to rupture and cause 
thrombosis, leading to narrow or occlusion of artery and 
myocardial infarction. For those patients who have already 
had myocardial infarction, or, for those patients who are 
very susceptible to myocardial infarction, taking statins only 
is not much effective. Percutaneous coronary intervention 
(PCI), one medical operation, was developed to treat the 
occlusive (narrowed) coronary arteries. It was first devel-
oped in 1977. By the mid-1980s, many leading medical 
centers throughout the world were adopting the procedure 
as a treatment for coronary artery disease (CAD). Now, PCI 
is widely used in clinical practice. The usage of PCI signif-
icantly decreased mortality of CVD [25].  
Overall, from Framingham Heart Study to the develop-
ment of statin to PCI treatment, many successful transla-
tional studies in CVD have been done. These examples are 
all good examples of patient-oriented “Bedside to Bench to 
Bedside” translational research.  
Nowadays, CVD is still severe. It is estimated that CVD 
accounts for 29% of all-cause death in the world nowadays 
[26]. In China, it is estimated that the number of patients 
with CVD is 230 million, which means 2 out of 10 adults 
are afflicted with CVD [27]. However, in clinical practice, 
there are many limits to the currently available clinical 
methods. Firstly, for some patients, statin treatment may 
cause mild to severe side effects, including muscle pain, 
muscle damage and liver damage. Thus, those patients can-
not tolerate statin treatment. Secondly, for those patients 
taking PCI, restenosis often occurs after several months, so 
other effective drugs or methods preventing restenosis are 
urgently needed. Thirdly, the economic cost for treating or 
curing CVD nowadays is still very high. For these reasons, 
it is important to create more convenient and low cost 
methods or strategies to prevent CVD. 
Recently, calorie restriction was found to be a promising 
and practical strategy for preventing CVD. Calorie re-
striction means reducing total calorie intake to 60%–70% of 
that from usual diet without malnutrition [28,29]. One 
long-term report in rhesus monkey shows that, compared to 
normal diet, calorie restriction reduces incidence of aging 
associated CVD by a half [30]. Calorie restriction com-
pletely prevents aging associated glucoregulatory impair-
ment which is highly incident in normal diet [30]. In human, 
calorie restriction was reported to reduce risk factors for 
CVD such as total cholesterol, LDL cholesterol, triglyceride, 
fasting glucose, fasting insulin, CRP and blood pressure, but 
increased beneficial factors such as HDL cholesterol [31]. 
More directly and convincingly, calorie restriction was 
shown to reduce carotid artery intima medium thickness 
(IMT), which is an indicator of atherosclerotic plaque [31]. 
Therefore, calorie restriction is very effective in preventing 
CVD. Calorie restriction is easy to operate. It provides a 
convenient and effective method to promote health and 
prevent diseases. Metabolism is the basic characteristic of 
human body. Calorie restriction may change the status of 
human body through changing metabolism, and, while short 
term calorie restriction leads to subtle quantitative change of 
metabolic profile, long term calorie restriction may result in 
great qualitative change of metabolic profile, shifting the 
human body from a status of calorie accumulation to a sta-
tus with appropriate calorie.  
The role of calorie restriction for treating diseases and its 
molecular mechanisms were widely studied in recent years. 
SIRT1, an NAD dependent class III deacetylase, is im-
portant for mediating effect of calorie restriction [28,32,33]. 
There are diverse beneficial effects for SIRT1 in preventing 
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atherosclerosis. SIRT1 upregulates eNOS expression but 
inhibits p66shc gene expression in endothelial cells, both of 
which prevent endothelial dysfunction [34,35]. PGE2 and 
COX2 are two molecules promoting inflammation and ath-
erosclerosis formation. In macrophages, SIRT1 inhibits 
COX2 expression and PGE2 production and inhibits in-
flammation [36], and also decrease Lox-1 mediated foam 
cell formation [37]. Neointima formation is a common 
event after intervention therapy in clinical practice. In mice, 
SIRT1 was found to inhibit neointima formation by sup-
pressing smooth muscle cell proliferation and migration 
[38]. Thus, SIRT1 may be a target for preventing neointima 
formation in human after PCI operation. 
To promote translational research, it is required to set up 
translational research centers and cultivate a large number 
of talents who are engaged in translational research. Today, 
many translational research centers have been built up and 
numerous translational research programs have been carried 
out. These centers provide good hardware and the programs 
offer good human resources for translational research.   
In China, many translational research centers have been 
built or are under construction. Specific examples for trans-
lational research centers which have been built include 
Translational Medicine Center of Chinese Academy of 
Medical Sciences and Peking Union Medical College in 
Beijing, Northeast Clinical and Translational Medicine 
Center in Harbin, and many translational medicine centers 
in other major cities, including Shanghai, Hangzhou, 
Guangzhou, Changsha and Nanjing. Some centers are under 
construction.  
Currently, there are some programs available for transla-
tional research in China. First, there are eight-year programs 
for medical students in some medical schools, including 
Peking Union Medical College and others. After clinical 
training, students are given eight-month research training, 
where they could learn theories, techniques for basic re-
search and do some research. Therefore, these students have 
good background for both clinical research and basic re-
search. Second, China has a large number of medical grad-
uates who received five-year programs. Some of them 
passed examinations and go to research institutes or schools 
as masters to engage in basic research. These graduate stu-
dents, with good background for clinics, provide potential 
human resource for translational research. In China, current 
government supports for translational research include 
funding of the National Natural Science Foundation of 
China for applied medical research, broad support for sci-
ence and technology projects from the National Basic Re-
search  Program of China (973), and Science and Tech-
nology Special Projects support for research in drug discov-
ery and infectious disease.  
Translational research needs “translational integration” 
of multidisciplines, including epidemiology, basic medicine, 
drug discovery and new techniques. It should promote ex-
changes and cooperations among different disciplines and 
build platforms to integrate hardware, software and talents. 
Today, with the coming of globalization and development 
of information technology, exchanges among people are 
becoming more feasible, frequent and effective than ever. 
Cooperation in a wide range is possible. Some national pro-
grams to promote translational research in China, such as 
Key Drug Innovation Program, are carried out. As an inter-
national cooperation, Sino-US Translational Research 
Symposium was held in Beijing in 2010 and in Shanghai in 
2011. These programs greatly promoted translational inte-
gration from different disciplines.  
The set up of translational research centers, the cultiva-
tion of translational research talents, and the cooperation 
among different disciplines, all put forward the rapid de-
velopment of translational research nowadays. With the 
development of translational research in CVD or in other 
diseases, such as cancer, more and more strategies and 
methods for preventing, diagnosing or treating diseases will 
be achieved and benefit human health.  
The ultimate goal for translational research may be to re-
alize “9P” medicine, which includes protecting health, 
promoting health, prolonging healthy life span; predicting 
diseases, pre-warning diseases, preventing diseases; popula-
tion policy, personal participation, and personalized medi-
cine. Among these, prolonging healthy life span, preventing 
diseases and personalized medicine may be the most im-
portant and can be called “3P” medicine. The “9P-3P” 
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